surveillance. Instead, we found CD11c+ immune cells embedded in collagen. LAIR1+
immune cells were found to be enriched in regions of collagen, indicating a potentially
previously unappreciated mechanism of glioma-mediated immune suppression (Figure 1I).
Currently, there is a phase I trial of a LAIR1 antagonist in myeloid malignancies (NextCure
NCT05787496) that could be considered as a new treatment for …